Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure

Despite the high efficacy of direct acting antivirals (DAAs) not all patients successfully clear hepatitis C virus infection, in fact, approximately 1–3% fail to reach a sustained virological response 12 weeks after end of treatment. DAA failures are characterized by advanced liver disease, specific...

Descripción completa

Detalles Bibliográficos
Autores principales: Parigi, Tommaso Lorenzo, Torres, Maria Corina Plaz, Aghemo, Alessio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933124/
https://www.ncbi.nlm.nih.gov/pubmed/31042864
http://dx.doi.org/10.3350/cmh.2019.0022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933124/
https://www.ncbi.nlm.nih.gov/pubmed/31042864
http://dx.doi.org/10.3350/cmh.2019.0022

Ejemplares similares